Lorenzi M V, Castagnino P, Chen Q, Chedid M, Miki T
Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892, USA.
Oncogene. 1997 Aug 14;15(7):817-26. doi: 10.1038/sj.onc.1201242.
To assess the effect(s) of the C-terminal domain on FGFR2 function, we engineered a series of mutant FGFR2 cDNAs encoding deletions in the C-terminus of the receptor and compared their growth properties in NIH3T3 fibroblasts. In contrast to FGFR2-WT, receptors with C-terminal truncations induced ligand-independent transformation of NIH3T3 cells and transfectants expressing these mutant receptors efficiently formed colonies in semisolid medium. Introduction of point mutations (Y to F) into the C-terminus of FGFR2 at positions 813, 784 or 780 revealed that these mutant receptors also displayed activities similar to that of C-terminally truncated receptors. C-terminally altered FGF receptors did not show an increase in the basal level of receptor phosphorylation compared to that of FGFR2-WT suggesting that elevated receptor phosphorylation does not underlie the transforming activity of these receptors. Interestingly, expression of transforming FGFR2 derivatives, unlike H-Ras transformed cells, did not result in the activation of the mitogen-activated protein kinases (MAPKs), p42/ERK2 and p44/ERK1, indicating that this pathway is not constitutively active in FGFR2-transformed cells. Finally, we report the overexpression of FGFR2 mRNA and protein in several human tumor cell lines suggesting activation of the receptor in these tumors.
为了评估C末端结构域对FGFR2功能的影响,我们构建了一系列编码受体C末端缺失的突变型FGFR2 cDNA,并比较了它们在NIH3T3成纤维细胞中的生长特性。与FGFR2-WT相反,具有C末端截短的受体诱导NIH3T3细胞发生不依赖配体的转化,表达这些突变受体的转染子在半固体培养基中能高效形成集落。在FGFR2的C末端第813、784或780位引入点突变(Y突变为F)表明,这些突变受体也表现出与C末端截短受体相似的活性。与FGFR2-WT相比,C末端改变的FGF受体的受体磷酸化基础水平并未增加,这表明受体磷酸化升高并非这些受体转化活性的基础。有趣的是,与H-Ras转化细胞不同,转化型FGFR2衍生物的表达并未导致丝裂原活化蛋白激酶(MAPK)p42/ERK2和p44/ERK1的激活,这表明该途径在FGFR2转化细胞中并非组成性激活。最后,我们报道了FGFR2 mRNA和蛋白在几种人类肿瘤细胞系中的过表达,提示这些肿瘤中受体被激活。